Hepion gets FDA feedback on opioid-overdose prevention drug GV104 Oct 26, 2026 08:01AM
Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest Oct 26, 2026 08:01AM
Hepion unit gets FDA feedback on GV104 for gambling disorder Oct 19, 2026 08:06AM
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication Oct 19, 2026 08:01AM
Hepion Pharmaceuticals acquires Gravitas Life Sciences, adds two programs Oct 14, 2026 08:01AM


Oct 14, 2026 08:01AM Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
May 12, 2025 04:30PM Hepion Pharmaceuticals (HEPA) Announces Receipt of Delisting Notification from Nasdaq
May 7, 2025 08:31AM Hepion Pharmaceuticals (HEPA) Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
Mar 14, 2025 08:30AM Hepion Pharmaceuticals (HEPA) Announces 1-for-50 Reverse Stock Split
Jan 22, 2025 08:00AM Hepion Pharmaceuticals (HEPA) Prices $9M Offering
Dec 11, 2024 08:01AM Hepion Pharmaceuticals (HEPA) Terminates Merger Agreement with Pharma Two B Ltd.
Dec 2, 2024 08:01AM Hepion Pharmaceuticals (HEPA) Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Nov 11, 2024 08:03AM Pharma Two B and Hepion Pharmaceuticals (HEPA) Announce Effectiveness of Registration Statement Related to Proposed Merger
Sep 4, 2024 09:26AM Hepion Pharmaceuticals (HEPA) and Pharma Two B File Registration Statement on Form F-4 Related to Proposed Merger
Jul 22, 2024 08:03AM Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals (HEPA) and Concurrent $11.5 Million Private Placement